Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Updates on transplant for patients with myeloma

Sergio Giralt • 22 Feb 2021
TCT 2021
Multiple Myeloma Carfilzomib Daratumumab Lenalidomide

Sergio A. Giralt, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, provides an overview of the latest developments in the field of multiple myeloma, including depth of response associated with a four-drug induction, as well as the use of combined carfilzomib lenalidomide maintenance therapy as evaluated in a recent study. Dr Giralt continues to discuss the role of allogeneic transplantation in patients with multiple myeloma and highlights the need for a better understanding of how to sequence therapies for patients. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Sergio Giralt

1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:59
The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt • 8 Dec 2023
2:03
The evolving role of transplantation in multiple myeloma in the age of novel immunotherapeutics
Sergio Giralt • 8 Dec 2023
1:29
Final results of KarMMa-3: ide-cel in R/R MM
Sergio Giralt • 8 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals